Saturday 17 October 2026
Export KRYS’s income statement to Excel — free account
Krystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024. In the quarter to June 2026, revenue grew 24.1%, EPS grew 39.1% and free cash flow grew 40.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
316.58
13.42
−4.07%
Follow KRYS
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | — | 7 |
P/E ratio |
— | — | — | — | — | — | — | 694.22 | 50.54 | 34.82 |
P/S ratio |
— | — | — | — | — | — | — | 0.00 | 15.42 | 18.34 |
Altman Z-Score |
— | — | — | — | — | — | — | 50.87 | 25.52 | 39.03 |
P/FCF ratio |
— | — | — | — | — | — | — | 0.00 | 37.58 | 37.69 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | — | 23.06 | 12.92 | 16.61 |
Beneish M-Score |
— | — | — | — | — | — | — | — | 1.05 | (2.27) |
P/Operating CF |
— | — | — | — | — | — | — | (469.19) | 84.76 | 92.07 |
P/B ratio |
— | — | — | — | — | — | — | 4.36 | 4.73 | 5.85 |
Price to Tangible BV |
— | — | — | — | — | — | — | 4.36 | 4.73 | 5.85 |
EV/Sales |
— | — | — | — | — | — | — | 0.00 | 13.36 | 16.21 |
EV/EBITDA |
— | — | — | — | — | — | — | 0.00 | 53.57 | 37.58 |
EV/Operating CF |
— | — | — | — | — | — | — | (32.22) | 31.45 | 31.40 |
EV/FCF |
— | — | — | — | — | — | — | (4,744.59) | 32.57 | 33.31 |
Quick Ratio |
44.72 | 77.49 | 43.05 | 58.22 | 17.56 | 17.02 | 13.14 | 17.35 | 6.89 | 9.28 |
Current Ratio |
50.44 | 77.99 | 43.39 | 58.88 | 17.80 | 17.18 | 13.30 | 17.76 | 7.28 | 9.95 |
Net Debt/EBITDA |
0.07 | 10.44 | 9.49 | 9.23 | 8.71 | 6.69 | 2.67 | 5.13 | (8.25) | (4.93) |
Debt/Assets |
84.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
6.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.31 | 0.33 |
Operating CF/Net income |
1.14 | 0.49 | 0.87 | 0.98 | 0.81 | 0.69 | 0.72 | (8.12) | 1.38 | 0.98 |
Capex/Depreciation |
(7.50) | (9.13) | (15.84) | (5.87) | (8.02) | (24.68) | (15.65) | 14.92 | (0.63) | (1.76) |
Interest Coverage |
(163.29) | (1.52) | (11.60) | (7.38) | (39.66) | (45.76) | (27.81) | — | — | — |
| (4.76%) | (32.76%) | (13.39%) | (12.08%) | (13.00%) | (15.71%) | (25.09%) | 1.68% | 10.34% | 18.91% | |
| (4.40%) | (30.29%) | (13.10%) | (11.74%) | (12.38%) | (14.85%) | (23.63%) | 1.59% | 9.51% | 17.14% | |
ROIC |
(341.81%) | 0.00% | (508.36%) | (149.54%) | (99.05%) | (27.45%) | (63.43%) | (27.80%) | 11.78% | 25.73% |
Return on Tangible Assets |
(53.76%) | (16.01%) | (9.63%) | (9.50%) | (11.07%) | (13.15%) | (27.09%) | 1.53% | 11.21% | 19.10% |
Average Days of Receivables |
— | — | — | — | — | — | — | 302.66 | 131.60 | 119.52 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 91.59% | 18.44% | 14.92% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 193.87% | 39.11% | 37.71% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 78.76% | 16.91% | 14.01% |
Graham Net Nets |
— | — | — | — | — | — | — | 0.16 | 0.14 | 0.13 |
Graham Number |
— | — | — | — | — | — | — | 10.78 | 48.05 | 81.93 |
Earnings Yield |
— | — | — | — | — | — | — | 0.14% | 1.98% | 2.87% |
Free Cash Flow Yield |
— | — | — | — | — | — | — | (0.02%) | 2.66% | 2.65% |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.87 | 10.16 | 13.44 |
Operating CF per Share |
(1.49) | (0.73) | (0.84) | (1.18) | (1.39) | (2.16) | (3.95) | (3.27) | 4.32 | 6.94 |
Capex per Share |
(0.02) | (0.04) | (0.20) | (0.40) | (0.79) | (3.08) | (2.08) | 3.25 | (0.15) | (0.40) |
Free Cash Flow per Share |
(1.51) | (0.76) | (1.04) | (1.58) | (2.18) | (5.24) | (6.02) | (0.02) | 4.17 | 6.54 |
Cash per Share |
2.19 | 9.25 | 9.98 | 12.18 | 14.44 | 19.74 | 14.87 | 19.60 | 20.90 | 28.60 |
Shareholders Equity per Share |
0.33 | 9.23 | 10.11 | 12.76 | 15.55 | 26.74 | 20.49 | 28.68 | 33.10 | 42.14 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.33 | 9.23 | 10.11 | 12.76 | 15.55 | 26.74 | 20.49 | 28.68 | 33.10 | 42.14 |
Free Cash Flow |
(1.33) | (4.10) | (11.68) | (25.09) | (40.93) | (116.27) | (153.55) | (0.60) | 119.18 | 189.35 |
Working Capital |
2.13 | 49.27 | 110.05 | 192.55 | 259.61 | 416.53 | 354.93 | 554.82 | 640.05 | 921.66 |
Capital Expenditures |
(0.01) | (0.21) | (2.23) | (6.40) | (14.84) | (68.34) | (52.98) | 88.20 | (4.24) | (11.52) |
Net Current Asset Value |
0.28 | 49.27 | 109.76 | 189.77 | 256.30 | 409.55 | 347.56 | 548.20 | 632.59 | 910.37 |
EV/EBIT |
— | — | — | — | — | — | — | 0.00 | 59.04 | 39.11 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.74) | 0.01 | 0.03 |
Price to Operating Income |
— | — | — | — | — | — | — | 0.00 | 68.13 | 44.24 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.15 | 0.12 | 0.05 | 0.13 | 0.06 | 0.02 | 0.02 | 0.04 | 0.04 | 0.04 |
Cash ROIC |
(32.70%) | (4.14%) | (5.19%) | (6.33%) | (7.26%) | (11.27%) | (17.03%) | (0.05%) | 7.72% | 9.25% |
Accounts Receivable Turnover |
— | — | — | — | — | — | — | 0.00 | 3.96 | 3.35 |
Accounts Payable Turnover |
0.02 | 0.20 | 0.26 | 1.02 | 1.18 | 0.53 | 0.66 | 0.76 | 4.40 | 5.61 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20 | 0.69 |
Average Days of Payables |
7,665.00 | 3,062.83 | 2,298.72 | 382.61 | 415.09 | 1,107.00 | 358.34 | 487.45 | 90.70 | 51.28 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 824.02 | 482.30 | 640.96 |
Average Receivables |
— | — | — | — | — | — | — | — | 73.39 | 116.09 |
Average Payables |
0.12 | 0.12 | 0.54 | 0.95 | 1.56 | 5.25 | 6.19 | 4.06 | 4.56 | 4.11 |
Average Inventory |
— | — | — | — | — | — | — | — | 16.75 | 33.49 |
Average Assets |
26.15 | 26.15 | 83.12 | 162.57 | 259.93 | 468.57 | 592.37 | 688.40 | 937.10 | 1,194.82 |
Average Common Equity |
24.18 | 24.18 | 81.35 | 158.07 | 247.50 | 442.83 | 557.90 | 650.44 | 862.51 | 1,082.97 |
Columns are period end dates